B cells and antibodies in progressive multiple sclerosis: Contribution to neurodegeneration and progression

Autoimmunity Reviews

Volumn 15, Issue 9, 2016, Pages 896-899

  Fraussen, Judith ^a   de Bock, Laura ^a   Somers, Veerle ^a  

^a HASSELT UNIVERSITY   (Belgium)

Author keywords

Antibodies; B cells; Central nervous system; Multiple sclerosis; Sperm associated antigen 16

Indexed keywords

AUTOANTIBODY; B LYMPHOCYTE ANTIBODY; IMMUNOGLOBULIN M; OLIGOCLONAL BAND; SPERM ASSOCIATED ANTIGEN 16 ANTIBODY; UNCLASSIFIED DRUG;

B LYMPHOCYTE; DISEASE COURSE; HUMAN; IMMUNOGLOBULIN PRODUCTION; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NONHUMAN; REVIEW; ANIMAL; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY;

ANIMALS; AUTOANTIBODIES; B-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; DISEASE PROGRESSION; HUMANS; IMMUNOGLOBULIN M; INFLAMMATION; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NEURODEGENERATIVE DISEASES;

EID: 85002675978     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.07.008     Document Type: Review

References (36)

1. [1] Karussis, D., The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun 48–49 (2014), 134–142.
2. [2] Lublin, F.D., Reingold, S.C., Cohen, J.A., Cutter, G.R., Sorensen, P.S., Thompson, A.J., et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83 (2014), 278–286.
3. [3] Lassmann, H., Bruck, W., Lucchinetti, C.F., The immunopathology of multiple sclerosis: an overview. Brain Pathol 17 (2007), 210–218.
4. [4] Cole, S.R., Beck, R.W., Moke, P.S., Kaufman, D.I., Tourtellotte, W.W., The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Opt Neuritis Study Group Neurol 51 (1998), 885–887.
5. [5] Fraussen, J., Claes, N., de Bock, L., Somers, V., Targets of the humoral autoimmune response in multiple sclerosis. Autoimmun Rev 13 (2014), 1126–1137.
6. [6] Ramanathan, S., Dale, R.C., Brilot, F., Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev 15 (2015), 307–324.
7. [7] Stern, J.N., Yaari, G., Vander Heiden, J.A., Church, G., Donahue, W.F., Hintzen, R.Q., et al. B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Sci Transl Med, 6, 2014 [248ra107].
8. [8] Vrolix, K., Fraussen, J., Losen, M., Stevens, J., Lazaridis, K., Molenaar, P.C., et al. Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor. J Autoimmun 52 (2014), 101–112.
9. [9] Bao, Y., Cao, X., The immune potential and immunopathology of cytokine-producing B cell subsets: a comprehensive review. J Autoimmun 55 (2014), 10–23.
10. [10] Lassmann, H., New concepts on progressive multiple sclerosis. Curr Neurol Neurosci Rep 7 (2007), 239–244.
11. [11] Frischer, J.M., Bramow, S., Dal-Bianco, A., Lucchinetti, C.F., Rauschka, H., Schmidbauer, M., et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132 (2009), 1175–1189.
12. [12] Komori, M., Blake, A., Greenwood, M., Lin, Y.C., Kosa, P., Ghazali, D., et al. Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis. Ann Neurol 78 (2015), 3–20.
13. [13] Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E., Aloisi, F., Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14 (2004), 164–174.
14. [14] Howell, O.W., Reeves, C.A., Nicholas, R., Carassiti, D., Radotra, B., Gentleman, S.M., et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134 (2011), 2755–2771.
15. [15] Magliozzi, R., Howell, O., Vora, A., Serafini, B., Nicholas, R., Puopolo, M., et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130 (2007), 1089–1104.
16. [16] Fischer, M.T., Wimmer, I., Hoftberger, R., Gerlach, S., Haider, L., Zrzavy, T., et al. Disease-specific molecular events in cortical multiple sclerosis lesions. Brain 136 (2013), 1799–1815.
17. [17] Cepok, S., Jacobsen, M., Schock, S., Omer, B., Jaekel, S., Boddeker, I., et al. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 124 (2001), 2169–2176.
18. [18] Fyfe, I., In the news: ocrelizumab excites ectrims. Nat Rev Neurol, 11, 2015, 667.
19. [19] Studer, V., Rossi, S., Motta, C., Buttari, F., Centonze, D., Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive multiple sclerosis. J Neuroimmunol 276 (2014), 229–231.
20. [20] Romme Christensen, J., Bornsen, L., Ratzer, R., Piehl, F., Khademi, M., Olsson, T., et al. Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. PLoS One, 8, 2013, e57820.
21. [21] Comabella, M., Canto, E., Nurtdinov, R., Rio, J., Villar, L.M., Picon, C., et al. MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes. Hum Mol Genet 25 (2016), 308–316.
22. [22] Fitzner, B., Hecker, M., Zettl, U.K., Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients. Autoimmun Rev 14 (2015), 903–913.
23. [23] Villar, L.M., Sadaba, M.C., Roldan, E., Masjuan, J., Gonzalez-Porque, P., Villarrubia, N., et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 115 (2005), 187–194.
24. [24] Villar, L.M., Masjuan, J., Gonzalez-Porque, P., Plaza, J., Sadaba, M.C., Roldan, E., et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 53 (2003), 222–226.
25. [25] Thangarajh, M., Gomez-Rial, J., Hedstrom, A.K., Hillert, J., Alvarez-Cermeno, J.C., Masterman, T., et al. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Mult Scler 14 (2008), 1208–1213.
26. [26] Villar, L.M., Casanova, B., Ouamara, N., Comabella, M., Jalili, F., Leppert, D., et al. Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. Ann Neurol 76 (2014), 231–240.
27. [27] Villar, L.M., Picon, C., Costa-Frossard, L., Alenda, R., Garcia-Caldentey, J., Espino, M., et al. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis. Eur J Neurol 22 (2015), 1169–1175.
28. [28] D'Ambrosio, A., Pontecorvo, S., Colasanti, T., Zamboni, S., Francia, A., Margutti, P., Peripheral blood biomarkers in multiple sclerosis. Autoimmun Rev 14 (2015), 1097–1110.
29. [29] Alvarez-Cermeno, J.C., Munoz-Negrete, F.J., Costa-Frossard, L., de la Maza, S.S., Villar, L.M., Rebolleda, G., Intrathecal lipid-specific oligoclonal IgM synthesis associates with retinal axonal loss in multiple sclerosis. J Neurol Sci 360 (2016), 41–44.
30. [30] Somers, V., Govarts, C., Somers, K., Hupperts, R., Medaer, R., Stinissen, P., Autoantibody profiling in multiple sclerosis reveals novel antigenic candidates. J Immunol 180 (2008), 3957–3963.
31. [31] de Bock, L., Somers, K., Fraussen, J., Hendriks, J.J., van Horssen, J., Rouwette, M., et al. Sperm-associated antigen 16 is a novel target of the humoral autoimmune response in multiple sclerosis. J Immunol 193 (2014), 2147–2156.
32. [32] de Bock, L., Fraussen, J., Villar, L.M., Alvarez-Cermeno, J.C., Van Wijmeersch, B., van Pesch, V., et al. Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index. Eur J Neurol 23 (2015), 722–728.
33. [33] Zhang, Z., Kostetskii, I., Tang, W., Haig-Ladewig, L., Sapiro, R., Wei, Z., et al. Deficiency of SPAG16L causes male infertility associated with impaired sperm motility. Biol Reprod 74 (2006), 751–759.
34. [34] Silina, K., Zayakin, P., Kalnina, Z., Ivanova, L., Meistere, I., Endzelins, E., et al. Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients. J Immunother 34 (2011), 28–44.
35. [35] Brosnan, C.F., Raine, C.S., The astrocyte in multiple sclerosis revisited. Glia 61 (2013), 453–465.
36. [36] Sadatipour, B.T., Greer, J.M., Pender, M.P., Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 44 (1998), 980–983.